MedTrace Logo

Single Oral Dose of BeneFlax to Healthy Young and Older Adults

NCT01531569 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-10-26

No results posted yet for this study

Summary

This study is being done to look at age differences in the way the investigators bodies break down a compound found in flax seed (secoisolariciresinol diglucoside or SDG). It is administered to research subjects in a product called BeneFlax, which a concentrated version of flax seed containing 38% SDG.

It is known that as people age, their bodies undergo physical changes both on the outside and the inside. The aging process may change the way that the investigators bodies deal with compounds the investigators eat. As an important measure of safety, the investigators want to check for evidence whether there is a difference in break down of SDG between different age groups.

Conditions

Interventions

OTHER

BeneFlax - 38% secoisolariciresinol diglucoside (SDG)

0.8g of BeneFlax (contains 300mg SDG) given once by mouth

Sponsors & Collaborators

  • Saskatchewan Health Research Foundation

    collaborator OTHER

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Jane Alcorn, DVM, PhD · College of Pharmacy & Nutrition, University of Saskatchewan

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531569 on ClinicalTrials.gov